Immunovant Inc reports results for the quarter ended in September - Earnings Summary

Immunovant

04/11/2022 11:57

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 41 cents​​ per share for the quarter ended in September. The
mean expectation of nine analysts for the quarter was for a loss
of 39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 41
cents​.
    * The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Immunovant Inc shares had risen by 113.6% this quarter and
gained 39.9% so far this year.
    * The company reported a quarterly loss of $47.93 million.
    * Wall Street's median 12-month price target for Immunovant
Inc is
$7.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
4 at 11:57 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.39          -0.41          Missed
 Jun. 30 2022      -0.40          -0.35          Beat
 Mar. 31 2022      -0.38          -0.41          Missed
 Dec. 31 2021      -0.33          -0.36          Missed